Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 2/2018

01-06-2018 | short review

ASH 2017: highlights in chronic myeloid leukemia

Author: Klaus Geissler

Published in: memo - Magazine of European Medical Oncology | Issue 2/2018

Login to get access

Summary

Despite remarkable achievements in the management of chronic myeloid leukemia (CML), there remain a number of challenges in the field. At the American Society of Hematology (ASH) Meeting 2017 several presentations addressed current problems around the topics CML stem cells, progression of CML into blast crisis (BC), and personalized treatment.
Literature
1.
Valent P. Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept. Curr Cancer Drug Targets. 2011;11(1):56–71.CrossRefPubMed
2.
Bocchia M, Aprile L, Sirianni S, et al. Peripheral blood flow-cytometry chronic myeloid leukemia stem cells detection and Quantification during tyrosine kinase inhibitors therapy. Blood. 2016;128(issue22):abstr942.
3.
Bocchia M, Defina M, Sirianni S, et al. Persistence of residual circulating CD26+ leukemia stem cells in chronic myeloid leukemia patients in treatment free remission. Blood. 2017;130(suppl1):abstr249.
4.
Khorashad JS, Eiring AM, Mason CC, et al. shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. Blood. 2015;125(11):1772–81.CrossRefPubMedPubMedCentral
5.
Than H, Pomicter AD, Mason CC, et al. Inhibition of nucleocytoplasmic export enhances selective elimination of leukemic stem cells in chronic myeloid leukemia. Blood. 2017;130(suppl1):abstr42.
6.
7.
Gong Z, Medeiros LJ, Cortes JE, et al. Cytogenetics-based risk prediction of blastic transformation of CML treated with tyrosine kinase inhibitors. Blood. 2017;130(suppl1):abstr247.
8.
Branford S, Wang P, Yeung D, et al. Integrative genomics reveals cancer associated mutations are common at diagnosis of CML in patients with poor response to TKI therapy. Blood. 2017;130(suppl1):abstr251.
9.
Awad AS, Kankainen M, Eldfors S, et al. Identification of progression-associated mutations in Chronic Myeloid Leukemia (CML) by comparative genomic analysis. Blood. 2017;130(suppl1):abstr250.
10.
Mancini M, De Santis S, Monaldi C, et al. SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia. Blood. 2017;130(suppl1):abstr43.
11.
Magistroni V, Piazza R, Mauri M, et al. De novo UBE2A mutations are recurrently acquired during CML progression and interfere with myeloid differentiation pathways. Blood. 2017;130(suppl1):abstr44.
12.
Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol. 2010;28(16):2777–83.CrossRefPubMedPubMedCentral
13.
Hehlmann R, Lauseker M, Saussele S, et al. Final evaluation of randomized CML-study IV: 10-year survival and evolution of terminal phase. Blood. 2017;130(suppl1):abstr897.
14.
Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed Chronic Myeloid Leukemia: 12-month patient-reported outcomes from the BFORE trial. Blood. 2017;130(suppl1):abstr2895.
15.
Turkina AG, Shukhov O, Chelysheva E, et al. PF-114 mesylate, a novel third generation ATP-competitive BCR-ABL tyrosine kinase inhibitor: first safety and efficacy data from a phase I study in patients with CML with failure of prior TKI therapy. Blood. 2017;130(suppl1):abstr895.
16.
Saussele S, Richter J, Guilhot J, et al. “Duration of Deep Molecular Response” Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia—Results from the EURO-SKI Trial. Blood. 2017;130(suppl1):abstr313.
Metadata
Title
ASH 2017: highlights in chronic myeloid leukemia
Author
Klaus Geissler
Publication date
01-06-2018
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 2/2018
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-018-0406-0

Other articles of this Issue 2/2018

memo - Magazine of European Medical Oncology 2/2018 Go to the issue

short review

Chronic lymphocytic leukemia at ASH 2017

special report

My burning issues in aggressive Non Hodgkin’s Lymphoma

short review

Chimeric antigen receptor T‑cell therapy—a hematological success story

review

JAK2V617F allele burden: innovative concept in monitoring of myeloproliferative neoplasms

comment – reprint

Developments in neuro-oncology

short review

Update of clinical highlights presented at the 2017 American Society of Hematology Meeting
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits